Navigation Links
Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Date:2/11/2008

SUNNYVALE, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced publication of data characterizing the company's novel highly-selective histone deacetylase (HDAC) inhibitor. The study, entitled "A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas," appears in the February 7 issue of Leukemia.

Histone deacetylases are a family of related enzymes important in managing a multitude of cellular functions. HDAC inhibitors are a new class of drugs that modulate transcriptional activity in cells and may block angiogenesis and cell cycling, key components of tumor proliferation. HDAC inhibitors also appear to promote apoptosis (cell death) in tumor cells. Scientists have been searching for more selective inhibitors, which may offer the potential for treating a variety of diseases including cancer and inflammatory disorders while improving safety.

Results from the in-vitro study demonstrate that Pharmacyclics' proprietary HDAC inhibitor, PCI-34051, inhibits HDAC8 with 200-1000 fold selectivity over other HDAC enzymes. Studies showed that selective inhibition of HDAC8 inhibits cell growth and induces apoptosis in cell lines derived from T-cell lymphoma and leukemia, but not in other hematopoietic or solid tumor lines. This work also showed that HDAC8 selective inhibitors have a unique mechanism of action, and could play a role in T-cell lymphoma and other immune mediated diseases.

"To our knowledge, this is the first description of a truly selective HDAC isoform specific inhibitor," said Joseph J. Buggy, Ph.D., vice president of research for Pharmacyclics. "This study also confirms that individual HDAC isoforms have unique roles in cell physiology and it appears that the series of drug candidates we are developing may be useful in addressing diseases mediated by T-cells such as T-cell lymphomas or certain immune-mediated disorders."

The company's lead pan-HDAC inhibitor, PCI-24781, is currently in Phase 1 clinical trials in patients with solid and hematologic tumors.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and immune mediated diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about the initiation of and enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; our future capital requirements; and unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its quarterly report on Form 10-Q for the period ended December 31, 2007. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
2. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
3. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
4. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
5. Inverseon Announces Positive Phase IIa Asthma Study
6. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
7. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
8. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
9. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
10. InterCure Announces 100,000th RESPeRATE Unit Sold
11. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2017)... 2017  Opioid addiction and other drugs of abuse, ... and threatening outcomes, were problems taken on directly as ... that support them, met this week. This according to ... drugs of abuse, procalcitonin and acute kidney injury were ... 69th meeting in San Diego, CA. ...
(Date:8/2/2017)... 2017 CaryRx, a next-generation full-service pharmacy, has announced ... patients in the Washington D.C. metropolitan ... providing delivery of medications through the convenience of its patient-friendly ... delivered within one hour to any location in D.C. ... this invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... July 31, 2017 7D Surgical, developer of ground ... purchased the 7D Surgical System to support its strategic sales ... D.C. and Virginia.  7D Surgical has entered into ... of the premier medical facilities within those markets. ... ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 2017 , ... “Three Narrow Roads”: a vivid and provocative look into the ... Dr. Burnett King Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a ... Inc., a track-and-field program geared towards youth. , King shares, “When I take time ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin Care ... skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “We ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Steve the Snake”: an entertaining and ... is the creation of published author, Harold Flash Haskins Jr., a husband, father and ... Defense police officer. , “I write moral-based short stories for children and teens. My ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... care organizations and considered extremely effective, very effective, or effective by 85% of ... Leadership”. , NEJM Catalyst Insights Reports are based on surveys of the NEJM ...
(Date:8/17/2017)... ... August 17, 2017 , ... Industry CEOs, life science leaders, ... Rx. This off-the-record networking forum of the Boston Biotech Conference series will be ... Industry leaders and decision makers will discuss issues facing the development of anti-infective, ...
Breaking Medicine News(10 mins):